Biomerieux Alliance To Go For Stock Listing

2 April 1995

Biomerieux Alliance, the holding group that includes the diagnostics company BioMerieux and the French biotechnology group Transgene, is to be prepared for a stock exchange listing in three to five years time, according to Alain Merieux, who has a controlling 67% interest in the group.

Mr Merieux and the other shareholder, the CGIP group, plan to inject some 300 million French francs ($60.2 million) of new capital into Biomerieux Alliance. The core of the ensemble is BioMerieux, which has reported sustained growth in recent years.

In 1994, despite the 5% downturn in the European diagnostics market, BioMerieux increased its sales by 10% to 2.4 billion francs, with diagnostic tests for the detection of infectious diseases making up 80% of total turnover. Mr Merieux says the growth can be accelerated by alliances and acquisitions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight